Annual report

Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
MetricValuePeriodScopeSource row
Revenue¥290.8bn2025-04-01 → 2026-03-31Cons.Net sales
Revenue¥264.0bn2024-04-01 → 2025-03-31Cons.Net sales
Revenue¥180.1bn2023-04-01 → 2024-03-31vCons.Net sales (5-year summary)
Revenue¥170.0bn2022-04-01 → 2023-03-31vCons.Net sales (5-year summary)
Revenue¥166.2bn2021-04-01 → 2022-03-31vCons.Net sales (5-year summary)
Operating income¥14.8bn2025-04-01 → 2026-03-31Cons.Operating income
Operating income¥13.5bn2024-04-01 → 2025-03-31Cons.Operating income
Ordinary income¥14.9bn2025-04-01 → 2026-03-31Cons.Ordinary income
Ordinary income¥13.8bn2024-04-01 → 2025-03-31Cons.Ordinary income
Ordinary income¥9.3bn2023-04-01 → 2024-03-31vCons.Ordinary income loss (5-year summary)
Ordinary income¥10.1bn2022-04-01 → 2023-03-31vCons.Ordinary income loss (5-year summary)
Ordinary income¥10.1bn2021-04-01 → 2022-03-31vCons.Ordinary income loss (5-year summary)
Profit before tax¥14.4bn2025-04-01 → 2026-03-31Cons.Income before income taxes
Profit before tax¥12.8bn2024-04-01 → 2025-03-31Cons.Income before income taxes
Net income (owners)¥7.4bn2025-04-01 → 2026-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥5.2bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.9bn2023-04-01 → 2024-03-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥5.7bn2022-04-01 → 2023-03-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥5.5bn2021-04-01 → 2022-03-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income¥8.5bn2025-04-01 → 2026-03-31Cons.Profit loss
Net income¥7.5bn2024-04-01 → 2025-03-31Cons.Profit loss
Total assets¥158.1bnat 2026-03-31Cons.Assets
Total assets¥159.7bnat 2025-03-31Cons.Assets
Total assets¥117.8bnat 2024-03-31vCons.Total assets (5-year summary)
Total assets¥101.9bnat 2023-03-31vCons.Total assets (5-year summary)
Total assets¥96.0bnat 2022-03-31vCons.Total assets (5-year summary)
Total liabilities¥98.3bnat 2026-03-31Cons.Liabilities
Total liabilities¥97.5bnat 2025-03-31Cons.Liabilities
Net assets / equity¥59.8bnat 2026-03-31Cons.Net assets
Net assets / equity¥62.1bnat 2025-03-31Cons.Net assets
Net assets / equity¥52.8bnat 2024-03-31vCons.Net assets
Net assets / equity¥48.9bnat 2023-03-31vCons.Net assets (5-year summary)
Net assets / equity¥43.9bnat 2022-03-31vCons.Net assets (5-year summary)
Cash and deposits¥21.4bnat 2026-03-31Cons.Cash and deposits
Cash and deposits¥26.7bnat 2025-03-31Cons.Cash and deposits
Cash & equivalents¥21.0bnat 2026-03-31Cons.Cash and cash equivalents
Cash & equivalents¥26.4bnat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥26.9bnat 2024-03-31vCons.Cash and cash equivalents
Cash & equivalents¥18.6bnat 2023-03-31vCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥16.5bnat 2022-03-31vCons.Cash and cash equivalents (5-year summary)
Operating cash flow¥18.7bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥12.6bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥13.5bn2023-04-01 → 2024-03-31vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥11.7bn2022-04-01 → 2023-03-31vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥10.1bn2021-04-01 → 2022-03-31vCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥9.1bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥20.4bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥13.2bn2023-04-01 → 2024-03-31vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7.0bn2022-04-01 → 2023-03-31vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.1bn2021-04-01 → 2022-03-31vCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥15.0bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in financing activities
Financing cash flow¥7.2bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities
Financing cash flow¥8.0bn2023-04-01 → 2024-03-31vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥2.6bn2022-04-01 → 2023-03-31vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥10.0bn2021-04-01 → 2022-03-31vCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥197.352025-04-01 → 2026-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥137.972024-04-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥131.112023-04-01 → 2024-03-31vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥152.962022-04-01 → 2023-03-31vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥149.512021-04-01 → 2022-03-31vCons.Basic earnings loss per share (5-year summary)
Net assets per share¥1,528.91at 2026-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥1,521.14at 2025-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥1,414.43at 2024-03-31vCons.Net assets per share (5-year summary)
Net assets per share¥1,314.69at 2023-03-31vCons.Net assets per share (5-year summary)
Net assets per share¥1,189.7at 2022-03-31vCons.Net assets per share (5-year summary)
Equity ratio36.3%at 2026-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio35.8%at 2025-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio44.8%at 2024-03-31vCons.Equity to asset ratio (5-year summary)
Equity ratio47.9%at 2023-03-31vCons.Equity to asset ratio (5-year summary)
Equity ratio45.7%at 2022-03-31vCons.Equity to asset ratio (5-year summary)
ROE12.9%2025-04-01 → 2026-03-31Cons.Rate of return on equity (5-year summary)
ROE9.4%2024-04-01 → 2025-03-31Cons.Rate of return on equity (5-year summary)
ROE9.6%2023-04-01 → 2024-03-31vCons.Rate of return on equity (5-year summary)
ROE12.2%2022-04-01 → 2023-03-31vCons.Rate of return on equity (5-year summary)
ROE12.9%2021-04-01 → 2022-03-31vCons.Rate of return on equity (5-year summary)
Employees6,247at 2026-03-31Cons.Number of employees
Employees6,254at 2025-03-31Cons.Number of employees
Employees5,856at 2024-03-31vCons.Number of employees
Employees5,746at 2023-03-31vCons.Number of employees
Employees5,620at 2022-03-31vCons.Number of employees
Revenue¥11.2bn2025-04-01 → 2026-03-31StandaloneOperating revenue1
Revenue¥9.3bn2024-04-01 → 2025-03-31StandaloneOperating revenue1
Revenue¥8.7bn2023-04-01 → 2024-03-31vStandaloneOperating revenue1 (5-year summary)
Revenue¥8.3bn2022-04-01 → 2023-03-31vStandaloneOperating revenue1 (5-year summary)
Revenue¥7.0bn2021-04-01 → 2022-03-31vStandaloneOperating revenue1 (5-year summary)
Operating income¥9.1bn2025-04-01 → 2026-03-31StandaloneOperating income
Operating income¥7.3bn2024-04-01 → 2025-03-31StandaloneOperating income
Ordinary income¥8.9bn2025-04-01 → 2026-03-31StandaloneOrdinary income
Ordinary income¥7.3bn2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income¥7.0bn2023-04-01 → 2024-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥6.6bn2022-04-01 → 2023-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥5.5bn2021-04-01 → 2022-03-31vStandaloneOrdinary income loss (5-year summary)
Profit before tax¥8.9bn2025-04-01 → 2026-03-31StandaloneIncome before income taxes
Profit before tax¥6.4bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Net income¥8.8bn2025-04-01 → 2026-03-31StandaloneProfit loss
Net income¥6.5bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income¥6.7bn2023-04-01 → 2024-03-31vStandaloneNet income loss (5-year summary)
Net income¥6.6bn2022-04-01 → 2023-03-31vStandaloneNet income loss (5-year summary)
Net income¥5.4bn2021-04-01 → 2022-03-31vStandaloneNet income loss (5-year summary)
Total assets¥123.3bnat 2026-03-31StandaloneAssets
Total assets¥123.4bnat 2025-03-31StandaloneAssets
Total assets¥93.6bnat 2024-03-31vStandaloneTotal assets (5-year summary)
Total assets¥77.5bnat 2023-03-31vStandaloneTotal assets (5-year summary)
Total assets¥67.4bnat 2022-03-31vStandaloneTotal assets (5-year summary)
Total liabilities¥57.8bnat 2026-03-31StandaloneLiabilities
Total liabilities¥65.3bnat 2025-03-31StandaloneLiabilities
Net assets / equity¥65.5bnat 2026-03-31StandaloneNet assets
Net assets / equity¥58.2bnat 2025-03-31StandaloneNet assets
Net assets / equity¥52.5bnat 2024-03-31vStandaloneNet assets
Net assets / equity¥46.7bnat 2023-03-31vStandaloneNet assets (5-year summary)
Net assets / equity¥40.8bnat 2022-03-31vStandaloneNet assets (5-year summary)
Cash and deposits¥11.3bnat 2026-03-31StandaloneCash and deposits
Cash and deposits¥13.4bnat 2025-03-31StandaloneCash and deposits
EPS (basic)¥235.32025-04-01 → 2026-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥174.022024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥179.612023-04-01 → 2024-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥1782022-04-01 → 2023-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥146.912021-04-01 → 2022-03-31vStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥502025-04-01 → 2026-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥342024-04-01 → 2025-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥302023-04-01 → 2024-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥322022-04-01 → 2023-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥282021-04-01 → 2022-03-31vStandaloneDividend paid per share (5-year summary)
Net assets per share¥1,743.3at 2026-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,549.24at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,407.23at 2024-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥1,258.81at 2023-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥1,108.12at 2022-03-31vStandaloneNet assets per share (5-year summary)
Equity ratio53.1%at 2026-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio47.1%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio56.1%at 2024-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio60.3%at 2023-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio60.6%at 2022-03-31vStandaloneEquity to asset ratio (5-year summary)
ROE14.3%2025-04-01 → 2026-03-31StandaloneRate of return on equity (5-year summary)
ROE11.8%2024-04-01 → 2025-03-31StandaloneRate of return on equity (5-year summary)
ROE13.5%2023-04-01 → 2024-03-31vStandaloneRate of return on equity (5-year summary)
ROE15.0%2022-04-01 → 2023-03-31vStandaloneRate of return on equity (5-year summary)
ROE14.0%2021-04-01 → 2022-03-31vStandaloneRate of return on equity (5-year summary)
Shares issued38,902,785at 2026-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued38,902,785at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued38,902,785at 2024-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued38,902,785at 2023-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued38,902,785at 2022-03-31vStandaloneTotal number of issued shares (5-year summary)
Employees41at 2026-03-31StandaloneNumber of employees
Employees48at 2025-03-31StandaloneNumber of employees
Employees66at 2024-03-31vStandaloneNumber of employees
Employees66at 2023-03-31vStandaloneNumber of employees
Employees56at 2022-03-31vStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 69
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2025-04-01 → 2026-03-31¥56m
Reconciling Itemsreconcilingdepreciation2025-04-01 → 2026-03-31¥75m
Reconciling Itemsreconcilingrevenue2025-04-01 → 2026-03-31−¥1.6bn
Reconciling Itemsreconcilingrevenue intersegment2025-04-01 → 2026-03-31−¥1.6bn
Reconciling Itemsreconcilingsegment assetsat 2026-03-31−¥9.5bn
Reconciling Itemsreconcilingsegment profit2025-04-01 → 2026-03-31−¥3.8bn
BPOreportable segmentcapex2025-04-01 → 2026-03-31¥581m
BPOreportable segmentdepreciation2025-04-01 → 2026-03-31¥85m
BPOreportable segmentemployeesat 2026-03-31782 pure
BPOreportable segmentrevenue2025-04-01 → 2026-03-31¥15.7bn
BPOreportable segmentrevenue external2025-04-01 → 2026-03-31¥14.3bn
BPOreportable segmentrevenue intersegment2025-04-01 → 2026-03-31¥1.4bn
BPOreportable segmentsegment assetsat 2026-03-31¥8.3bn
BPOreportable segmentsegment profit2025-04-01 → 2026-03-31¥1.9bn
Health Insurance Pharmacyreportable segmentcapex2025-04-01 → 2026-03-31¥2.2bn
Health Insurance Pharmacyreportable segmentdepreciation2025-04-01 → 2026-03-31¥1.6bn
Health Insurance Pharmacyreportable segmentrevenue2025-04-01 → 2026-03-31¥177.6bn
Health Insurance Pharmacyreportable segmentrevenue external2025-04-01 → 2026-03-31¥177.5bn
Health Insurance Pharmacyreportable segmentrevenue intersegment2025-04-01 → 2026-03-31¥124m
Health Insurance Pharmacyreportable segmentsegment assetsat 2026-03-31¥93.9bn
Health Insurance Pharmacyreportable segmentsegment profit2025-04-01 → 2026-03-31¥9.7bn
Pharmaceutical Businessreportable segmentcapex2025-04-01 → 2026-03-31¥6.2bn
Pharmaceutical Businessreportable segmentdepreciation2025-04-01 → 2026-03-31¥3.6bn
Pharmaceutical Businessreportable segmentemployeesat 2026-03-31314 pure
Pharmaceutical Businessreportable segmentrevenue2025-04-01 → 2026-03-31¥99.0bn
Pharmaceutical Businessreportable segmentrevenue external2025-04-01 → 2026-03-31¥99.0bn
Pharmaceutical Businessreportable segmentsegment assetsat 2026-03-31¥65.4bn
Pharmaceutical Businessreportable segmentsegment profit2025-04-01 → 2026-03-31¥7.0bn
Pharmacyreportable segmentemployeesat 2026-03-315059 pure
—segment totalcapex2025-04-01 → 2026-03-31¥8.9bn
—segment totaldepreciation2025-04-01 → 2026-03-31¥5.3bn
—segment totalrevenue2025-04-01 → 2026-03-31¥292.3bn
—segment totalrevenue external2025-04-01 → 2026-03-31¥290.8bn
—segment totalrevenue intersegment2025-04-01 → 2026-03-31¥1.6bn
—segment totalsegment assetsat 2026-03-31¥167.6bn
—segment totalsegment profit2025-04-01 → 2026-03-31¥18.6bn
Reconciling Itemsreconcilingcapex2024-04-01 → 2025-03-31¥86m
Reconciling Itemsreconcilingdepreciation2024-04-01 → 2025-03-31¥66m
Reconciling Itemsreconcilingrevenue2024-04-01 → 2025-03-31−¥1.4bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2025-03-31−¥1.4bn
Reconciling Itemsreconcilingsegment assetsat 2025-03-31−¥9.9bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2025-03-31−¥3.5bn
BPOreportable segmentcapex2024-04-01 → 2025-03-31¥108m
BPOreportable segmentdepreciation2024-04-01 → 2025-03-31¥87m
BPOreportable segmentrevenue2024-04-01 → 2025-03-31¥14.9bn
BPOreportable segmentrevenue external2024-04-01 → 2025-03-31¥13.6bn
BPOreportable segmentrevenue intersegment2024-04-01 → 2025-03-31¥1.3bn
BPOreportable segmentsegment assetsat 2025-03-31¥8.6bn
BPOreportable segmentsegment profit2024-04-01 → 2025-03-31¥1.7bn
Health Insurance Pharmacyreportable segmentcapex2024-04-01 → 2025-03-31¥6.0bn
Health Insurance Pharmacyreportable segmentdepreciation2024-04-01 → 2025-03-31¥1.5bn
Health Insurance Pharmacyreportable segmentrevenue2024-04-01 → 2025-03-31¥171.7bn
Health Insurance Pharmacyreportable segmentrevenue external2024-04-01 → 2025-03-31¥171.6bn
Health Insurance Pharmacyreportable segmentrevenue intersegment2024-04-01 → 2025-03-31¥93m
Health Insurance Pharmacyreportable segmentsegment assetsat 2025-03-31¥94.8bn
Health Insurance Pharmacyreportable segmentsegment profit2024-04-01 → 2025-03-31¥10.0bn
Pharmaceutical Businessreportable segmentcapex2024-04-01 → 2025-03-31¥35.5bn
Pharmaceutical Businessreportable segmentdepreciation2024-04-01 → 2025-03-31¥2.2bn
Pharmaceutical Businessreportable segmentrevenue2024-04-01 → 2025-03-31¥78.7bn
Pharmaceutical Businessreportable segmentrevenue external2024-04-01 → 2025-03-31¥78.7bn
Pharmaceutical Businessreportable segmentsegment assetsat 2025-03-31¥66.2bn
Pharmaceutical Businessreportable segmentsegment profit2024-04-01 → 2025-03-31¥5.3bn
—segment totalcapex2024-04-01 → 2025-03-31¥41.6bn
—segment totaldepreciation2024-04-01 → 2025-03-31¥3.8bn
—segment totalrevenue2024-04-01 → 2025-03-31¥265.3bn
—segment totalrevenue external2024-04-01 → 2025-03-31¥264.0bn
—segment totalrevenue intersegment2024-04-01 → 2025-03-31¥1.4bn
—segment totalsegment assetsat 2025-03-31¥169.6bn
—segment totalsegment profit2024-04-01 → 2025-03-31¥17.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,621
ItemContextValueUnit
Official title or position information about directors and corporate auditors proposalFilingDateInstant_jpcrp030000-asr_E03476-000KazuoIshiiMember
Original text (Japanese)取締役(監査等委員)
Name information about directors and corporate auditors proposalFilingDateInstant_jpcrp030000-asr_E03476-000KazuoIshiiMember
Original text (Japanese)石井 和夫
Date of birth information about directors and corporate auditors proposalFilingDateInstant_jpcrp030000-asr_E03476-000KazuoIshiiMember1964-04-02
Career summary information about directors and corporate auditors proposal (text)FilingDateInstant_jpcrp030000-asr_E03476-000KazuoIshiiMemberText · Plus
Term of office information about directors and corporate auditors proposalFilingDateInstant_jpcrp030000-asr_E03476-000KazuoIshiiMember
Original text (Japanese)(注)5
Footnotes directors and corporate auditors proposal (text)FilingDateInstant_Row1MemberText · Plus
Footnotes directors and corporate auditors proposal (text)FilingDateInstant_Row2MemberText · Plus
Footnotes directors and corporate auditors proposal (text)FilingDateInstant_Row3MemberText · Plus
Footnotes directors and corporate auditors proposal (text)FilingDateInstant_Row4MemberText · Plus
Footnotes directors and corporate auditors proposal (text)FilingDateInstant_Row5MemberText · Plus
Outside directors and outside corporate auditors (text)FilingDateInstantText · Plus
Audits (text)FilingDateInstantText · Plus
Remuneration for directors and other officers (text)FilingDateInstantText · Plus
Remuneration etc paid by group to each director or other officer (text)FilingDateInstantText · Plus
Shareholdings (text)FilingDateInstantText · Plus
Name of securities details of specified investment equity securities held for purposes other than pure investment reporting companyCurrentYearInstant_Row1Member
Original text (Japanese)ニプロ株式会社
Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting companyCurrentYearInstant_Row1Member
Original text (Japanese)同社が製造するジェネリック医薬品を取扱っており、医薬品の流通における取引関係強化のために保有しております。
Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting companyCurrentYearInstant_Row1Member
Original text (Japanese)有
Name of securities details of specified investment equity securities held for purposes other than pure investment reporting companyCurrentYearInstant_Row2Member
Original text (Japanese)アルフレッサホールディングス株式会社
Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting companyCurrentYearInstant_Row2Member
Original text (Japanese)同社とは医薬品仕入に関する取引関係があり、医薬品の流通における取引関係強化のために保有しております。
Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting companyCurrentYearInstant_Row2Member
Original text (Japanese)無(注)2
Name of securities details of specified investment equity securities held for purposes other than pure investment reporting companyCurrentYearInstant_Row3Member
Original text (Japanese)株式会社メディカル一光グループ
Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting companyCurrentYearInstant_Row3MemberText · Plus
Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting companyCurrentYearInstant_Row3Member
Original text (Japanese)有
Footnotes specified investment shares held for purposes other than pure investment reporting company (text)CurrentYearInstant_Row1MemberText · Plus
Basic policy on human resources strategy employees etc (text)FilingDateInstantText · Plus
Information about employees (text)FilingDateInstantText · Plus
Reporting company metrics of reporting companyCurrentYearInstant_NonConsolidatedMember
Original text (Japanese)提出会社
Consolidated subsidiaries metrics of consolidated subsidiariesCurrentYearInstant_Row1Member
Original text (Japanese)クオール株式会社
Consolidated subsidiaries metrics of consolidated subsidiariesCurrentYearInstant_Row2Member
Original text (Japanese)株式会社共栄堂
Consolidated subsidiaries metrics of consolidated subsidiariesCurrentYearInstant_Row3Member
Original text (Japanese)アポプラスステーション株式会社
Consolidated subsidiaries metrics of consolidated subsidiariesCurrentYearInstant_Row4Member
Original text (Japanese)アポプラスキャリア株式会社
Consolidated subsidiaries metrics of consolidated subsidiariesCurrentYearInstant_Row5Member
Original text (Japanese)第一三共エスファ株式会社
Regulations in accordance with which consolidated financial statements have been prepared financial informationCurrentYearDurationText · Plus
Regulations in accordance with which financial statements have been prepared financial informationCurrentYearDurationText · Plus
Description of fact that financial statements have been prepared in accordance with special provision financial informationCurrentYearDuration
Original text (Japanese)なお、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。
Note on independent audit financial informationCurrentYearDurationText · Plus
Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial informationCurrentYearDurationText · Plus
Consolidated balance sheet (text)CurrentYearDurationText · Plus
Consolidated statement of income (text)CurrentYearDurationText · Plus
Consolidated statement of comprehensive income (text)CurrentYearDurationText · Plus
Consolidated statement of changes in equity (text)CurrentYearDurationText · Plus
Consolidated statement of cash flows (text)CurrentYearDurationText · Plus
Notes significant accounting policies for preparation of consolidated financial statements (text)CurrentYearDurationText · Plus
Number of consolidated subsidiaries and names of major consolidated subsidiaries (text)CurrentYearDurationText · Plus
Names of major unconsolidated subsidiaries and reasons for exclusion from scope of consolidation (text)CurrentYearDurationText · Plus
Names of major unconsolidated subsidiaries and associates and reasons for not being accounted for using equity method (text)CurrentYearDurationText · Plus
Disclosure about fiscal years etc of consolidated subsidiaries (text)CurrentYearDurationText · Plus
Disclosure of accounting policies (text)CurrentYearDurationText · Plus
Significant accounting estimates consolidated financial statements (text)CurrentYearDurationText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2025-03-31pass
balance sheet identityconsolidated 2026-03-31pass
balance sheet identitynon_consolidated 2025-03-31pass rounding
balance sheet identitynon_consolidated 2026-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2025-03-31pass
statement vs summary · net assetsconsolidated 2026-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net assetsnon_consolidated 2026-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2026-03-31pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenueconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenueconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2025-04-01/2026-03-31pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2026-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2026-03-31pass